Abstract
The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
MeSH terms
-
Adjuvants, Immunologic / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents, Immunological / therapeutic use*
-
BCG Vaccine / administration & dosage*
-
Clinical Trials, Phase II as Topic
-
Drug Approval*
-
Drug Resistance, Neoplasm
-
Humans
-
Multicenter Studies as Topic
-
Neoplasm Invasiveness
-
Neoplasm Staging
-
Survival Rate
-
United States
-
Urinary Bladder Neoplasms / drug therapy*
-
Urinary Bladder Neoplasms / immunology
-
Urinary Bladder Neoplasms / pathology
Substances
-
Adjuvants, Immunologic
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
BCG Vaccine
-
pembrolizumab